Last Update

2015-11-21T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Kimme Hyrich?

Dr. Kimme L. Hyrich

Professor of Epidemiology

The University of Manchester

Direct Phone: +44 **********       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

The University of Manchester

Oxford Road

Manchester, Manchester M13 9PR

United Kingdom

Company Description

The University of Manchester has been at the forefront of development studies for over 60 years. The Global Development Institute continues the commitment to addressing global poverty and inequality, by uniting the strengths of the Institute for Develop ... more

Find other employees at this company (16,614)

Background Information

Employment History

Senior Lecturer and Consultant In Rheumatology

Manchester City Council

Senior Lecturer In Rheumatic Disease Epidemiology

Manchester

Education

PhD

Web References (32 Total References)


Michael Mason Prize past winners | The British Society for Rheumatology

rheumatology.org.uk [cached]

Dr Kimme Hyrich University of Manchester


Kimme ...

www.inflammation-repair.manchester.ac.uk [cached]

Kimme Hyrich Professor of Epidemiology


Speakers are Prof Alex Macgregor (Chair), ...

www.rheumatology.org.uk [cached]

Speakers are Prof Alex Macgregor (Chair), Dr Kimme Hyrich and Dr Andrew Keat

...
Dr Kimme Hyrich, University of Manchester


Disclosures: Dr. Hyrich ...

www.oncologyreport.com [cached]

Disclosures: Dr. Hyrich reported having no relevant financial disclosures.

...
Overall, the risk of solid cancer with anti-TNF therapy does not appear to be increased," lead author Dr. Kimme Hyrich said at the annual meeting of the American College of Rheumatology.
"Of course this represents therapy only up to 5 years, and we know that cancer in general can take many, many years to develop or become clinically apparent. Therefore we need to continue to follow these patients," Dr. Hyrich noted.
The study corroborates previous studies showing a minimal cancer risk associated with the use of anti-TNF agents, many of which have been used in the treatment of RA for more than 10 years. "When they were first available for widespread use, I think there was a continuing anxiety about whether or not an agent, which blocks occult tumor necrosis factor, would actually increase the risk of cancer in patients with rheumatoid arthritis," said Dr. Hyrich, who is senior lecturer and consultant in rheumatology at the University of Manchester (England).
Studies since have been limited primarily to meta-analyses of randomized controlled trials of anti-TNF drugs. These trials tend to be of limited duration, and the participating patients tend to be highly screened. The participants may not represent patients in typical practice, Dr. Hyrich said.
...
Dr. Hyrich noted that there were differences between the two patient groups. In particular, more men were on DMARDs, and those on DMARDs were slightly older. "Both of these are recognized risk factors for cancer in general," he said. The results, however, were statistically adjusted to balance the risk between the two groups. The investigators found no significant differences between the groups after adjustment.
Dr. Hyrich reported having no relevant financial disclosures.


Disclosures: Dr. Hyrich ...

www.oncologyreport.com [cached]

Disclosures: Dr. Hyrich reported having no relevant financial disclosures.

...
Overall, the risk of solid cancer with anti-TNF therapy does not appear to be increased," lead author Dr. Kimme Hyrich said at the annual meeting of the American College of Rheumatology.
"Of course this represents therapy only up to 5 years, and we know that cancer in general can take many, many years to develop or become clinically apparent. Therefore we need to continue to follow these patients," Dr. Hyrich noted.
The study corroborates previous studies showing a minimal cancer risk associated with the use of anti-TNF agents, many of which have been used in the treatment of RA for more than 10 years. "When they were first available for widespread use, I think there was a continuing anxiety about whether or not an agent, which blocks occult tumor necrosis factor, would actually increase the risk of cancer in patients with rheumatoid arthritis," said Dr. Hyrich, who is senior lecturer and consultant in rheumatology at the University of Manchester (England).
Studies since have been limited primarily to meta-analyses of randomized controlled trials of anti-TNF drugs. These trials tend to be of limited duration, and the participating patients tend to be highly screened. The participants may not represent patients in typical practice, Dr. Hyrich said.
...
Dr. Hyrich noted that there were differences between the two patient groups. In particular, more men were on DMARDs, and those on DMARDs were slightly older. "Both of these are recognized risk factors for cancer in general," he said. The results, however, were statistically adjusted to balance the risk between the two groups. The investigators found no significant differences between the groups after adjustment.
Dr. Hyrich reported having no relevant financial disclosures.

Similar Profiles

Other People with this Name

Other people with the name Hyrich

Claire Hyrich
Advisian

Sean Hyrich
MongoLab

Cheryl Hyrich
ClaimBase Limited

Joe Hyrich
CH2M HILL Companies Ltd

Jolyn Hyrich
Stahl Peterbilt Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory